Results 201 to 210 of about 17,658 (223)

Nab-paclitaxel

Reactions Weekly
openaire   +1 more source

A Randomized, Controlled Phase III Trial of Nab-Paclitaxel Versus Dacarbazine in Chemotherapy-Naïve Patients With Metastatic Melanoma

Annals of Oncology, 2015
Michele Del Vecchio, Axel Hauschild, Shailender Bhatia   +2 more
exaly  

Safety and Efficacy Analysis by Histology of Weekly Nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

Annals of Oncology, 2013
V Hirsh, M A Socinski, S R Dakhil
exaly  

CA19-9 Decrease at 8 Weeks as a Predictor of Overall Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Annals of Oncology, 2016
David Goldstein, Josep Tabernero Caturla, Reni Michele   +2 more
exaly  

Does Nab-Paclitaxel Have a Higher Incidence of Peripheral Neuropathy Than Solvent-Based Paclitaxel? Evidence From a Systematic Review and Meta-Analysis

Critical Reviews in Oncology/Hematology, 2019
Yuhong Zhou, Hong Sun, Wei-Min Cai
exaly  

Positron Emission Tomography Response Evaluation From a Randomized Phase III Trial of Weekly Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Patients With Metastatic Adenocarcinoma of the Pancreas

Annals of Oncology, 2016
David Goldstein, Josep Tabernero Caturla, Salvatore Siena   +2 more
exaly  

Albumin-Bound Nanoparticle (Nab) Paclitaxel Exhibits Enhanced Paclitaxel Tissue Distribution and Tumor Penetration

Cancer Chemotherapy and Pharmacology, 2015
Maria Palmisano, Daniel W Pierce
exaly  

nab-Paclitaxel auch langfristig erfolgreich

Info Onkologie, 2015
openaire   +1 more source

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Case Medical Research, 2019
openaire   +1 more source

Metabolism of the Taxanes Including Nab-Paclitaxel

Expert Opinion on Drug Metabolism and Toxicology, 2015
Markus Joerger
exaly